Drug Res (Stuttg) 2013; 63(07): 370-375
DOI: 10.1055/s-0033-1341477
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetics of a New Immediate-release Compound Omeprazole Capsule and its Comparison with the Enteric-coated Formulation under Fasting and Fed Conditions

Z. Liu
1   Department of pharmaceutical analysis, China Pharmaceutical University, Tongjiaxiang, Nanjing, China
L. Ding
1   Department of pharmaceutical analysis, China Pharmaceutical University, Tongjiaxiang, Nanjing, China
S. Zhong
1   Department of pharmaceutical analysis, China Pharmaceutical University, Tongjiaxiang, Nanjing, China
X. Cao
2   Department of pharmacology, Jinling Hospital, Nanjing University, East Zhongshan Road, Nanjing, China
L. Jiang
1   Department of pharmaceutical analysis, China Pharmaceutical University, Tongjiaxiang, Nanjing, China
H. Duan
1   Department of pharmaceutical analysis, China Pharmaceutical University, Tongjiaxiang, Nanjing, China
› Institutsangaben
Weitere Informationen


received 19. November 2012

accepted 11. März 2013

04. April 2013 (online)


Background and Aims:

The present study was conducted to describe the pharmacokinetic profile of immediate-release compound omeprazole capsule and compare it with the enteric-coated formulation under fasting and fed condition.


This study was designed to phase I, open-label, randomized, 3-part clinical trial. 12 subjects in part one received single doses (20 mg and 40 mg) and repeated doses (20 mg). Different 30 subjects in part 2 (fasting condition) and part 3 (fed condition) received either compound omeprazole capsule (40 mg) or delayed-release omeprazole (40 mg) separated by 7 days.


Compound omeprazole capsule showed dose non-proportionality in the range from 20 mg to 40 mg. The AUC0–t of 20 mg omeprazole is 78% higher after repeated doses. The C max was higher and T max was lower for compound omeprazole capsule than delayed-release omeprazole. 90% CIs for AUC0–t of the 2 periods (test/reference) under fasting and fed conditions were 106.3% (102.2%~109.2%) and 104.1% (93.4%~109.6%), respectively. Presence of food reduced the rate (C max) and extent (AUC0–t) of systemic exposure of the test and reference formulations from 1 462 to 777 ng · mL−1, 1 055 to 602 ng · mL−1, 2 597 to 1 852 ng · h · mL−1 and 2 454 to 1 873 ng · h · mL−1, respectively.


Exposed dose of omeprazole in subjects with compound omeprazole capsule was time- and dose-dependent. Compared with delayed-release omeprazole, compound omeprazole capsule had rapid but similar degree of absorption of omeprazole.

  • References

  • 1 Raghunath AS, O’Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005; 22 (Suppl. 01) 55-63
  • 2 Holt S, Howden CW. Omeprazole. Overview and opinion. Dig Dis Sci 1991; 36: 385-393
  • 3 Pommerien W, Braun M, Idstrom JP et al. Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori-positive healthy subjects. Aliment Pharmacol Ther 1996; 10: 295-301
  • 4 Yang R, Schulman SG, Zavala PJ. Acid – base chemistry of omeprazole in aqueous solutions. Analytica Chimica Acta 2003; 481: 155-164
  • 5 El-Sherif ZA, Mohamed AO, El-Bardicy MG et al. Reversed-phase high performance liquid chromatographic method for the determination of lansoprazole, omeprazole and pantoprazole sodium sesquihydrate in presence of their Acid-induced degradation products. Chem Pharm Bull (Tokyo) 2006; 54: 814-818
  • 6 Sharma VK, Vasudeva R, Howden CW. The effects on intragastric acidity of per-gastrostomy administration of an alkaline suspension of omeprazole. Aliment Pharmacol Ther 1999; 13: 1091-1095
  • 7 Sharma VK, Peyton B, Spears T et al. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther 2000; 14: 887-892
  • 8 Song JC, Quercia RA, Fan C et al. Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension. Am J Health Syst Pharm 2001; 58: 689-694
  • 9 Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963-978
  • 10 Shimizu M, Uno T, Niioka T et al. Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 832: 241-248
  • 11 Shiohira H, Yasui-Furukori N, Tateishi T et al. Chiral assay of omeprazole and metabolites and its application to a pharmacokinetics related to CYP2C19 genotypes. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 2465-2470
  • 12 Sachs G, Shin JM, Briving C et al. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Annu Rev Pharmacol Toxicol 1995; 35: 277-305
  • 13 McQuaid KR, Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials. Clin Gastroenterol Hepatol 2005; 3: 553-563
  • 14 Immediate-release omeprazole . (IR-OME) Zegerid powder for oral suspension. Santarus Inc.; San Diego, CA, USA:
  • 15 McTavish D, Buckley MM, Heel RC. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 1991; 42: 138-170
  • 16 Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003; 63: 2739-2754
  • 17 Andersson T, Andren K, Cederberg C et al. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990; 29: 557-563
  • 18 Ko JW, Sukhova N, Thacker D et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: 853-862
  • 19 Hartmann M, Theiss U, Huber R et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996; 10: 359-366
  • 20 Desta Z, Zhao X, Shin JG et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-958
  • 21 Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-355
  • 22 Rost KL, Roots I. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology 1996; 23: 1491-1497
  • 23 Andersson T, Cederberg C, Regardh CG et al. Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur J Clin Pharmacol 1990; 39: 195-197
  • 24 Wo JM, Eversmann J, Mann S. Pharmacokinetic profile of immediate-release omeprazole in patients with gastro-oesophageal reflux associated with gastroparesis. Alimentary Pharmacology & Therapeutics 2010; 31: 516-522
  • 25 Howden CW. Review article: immediate-release proton-pump inhibitor therapy – potential advantages. Aliment Pharmacol Ther 2005; 22 (Suppl. 03) 25-30
  • 26 Katz PO, Koch FK, Ballard ED et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther 2007; 25: 197-205
  • 27 Vaz-da-Silva M, Loureiro AI, Nunes T et al. Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions. Clin Drug Investig 2005; 25: 391-399